References
- Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol. 2002; 40 (9): 3489–92.
- Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med. 1991; 91 (3B):865-895.
- Hadley S, Lee WW, Ruthazer R, Nasraway SA Jr. Candidemia as a cause of septic shock and multiple organ fail- ure in nonimmunocompromised patients. Crit Care Med. 2002; 30 (8): 1808–14.
- Chen TC, Chen YH, Tsai JJ, et al. Epidemiologic analy-sis and antifungal susceptibility of Candida blood isolates in southern Taiwan. J Microbiol Immunol Infect. 2005; 38 (3): 200–10.
- Luzzati R, Allegranzi B, Antozzi L, et al. Secular trends in nosocomial candidaemia in non-neutropenic patients in an Italian tertiary hospital. Clin Microbiol Infect. 2005; 11 (11): 908–13.
- Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med. 1988; 148 (12): 2642–5.
- Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treat-ment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994; 331 (20): 1325–30.
- Phillips P, Shafran S, Garber G, et al. Multicenter ran-domized trial of fluconazole versus amphotericin B for treat-ment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis. 1997; 16 (5): 337–45.
- Mora-Duarte J, Betts R, Rotstein C, et al. Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002; 347 (25): 2020–9.
- Pappas PG, Rex JH, Sobel JD, et al. Infectious Diseases Society of America. Guidelines for treatment of can-didiasis. Clin Infect Dis. 2004; 38 (2): 161–89.
- Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associat-ed treatment failure in Candida albicans endophthalmitis. Clin Infect Dis. 2005; 41 (3): e27–8.
- Nolla-Salas J, Sitges-Serra A, Leon C, de la Torre MV, Sancho H. Candida endophthalmitis in non-neutropenic criti-cally ill patients. Eur J Clin Microbiol Infect Dis. 1996; 15 (6): 503–6.
- Spellberg BJ, Filler SG, Edwards JE Jr. Current treat-ment strategies for disseminated candidiasis. Clin Infect Dis. 2006; 42 (2): 244–51.
- Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005; 366 (9495): 1435–42.
- Juster-Reicher A, Leibovitz E, Linder N, et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection. 2000; 28 (4): 223–6.
- Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma. 2001; 40(5-6):511–20.
- Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48: 693–715
- Meletiadis J, Petraitis V, Petraitiene R, et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis. 2006; 194 (7): 1008–18.